D-Cys Eptifibatide

D-Cys Eptifibatide, a synthetic cyclic heptapeptide containing a D-cysteine residue, represents a significant advancement in the field of carbohydrate-based compounds for scientific research and drug discovery. Characterized by its unique sequence and cyclic structure, D-Cys Eptifibatide exhibits enhanced stability and resistance to enzymatic degradation compared to its L-amino acid counterparts. This feature allows researchers to explore its bioactivity in a wide range of laboratory settings, particularly in studies focused on protein-protein interactions, receptor binding, and molecular recognition. The presence of the D-cysteine residue not only imparts stereochemical diversity but also provides a valuable handle for chemical modifications and conjugation strategies, expanding its utility in the development of molecular probes and functionalized biomolecules. As a result, D-Cys Eptifibatide has become an important tool in the exploration of integrin-mediated signaling pathways, platelet aggregation mechanisms, and the design of novel peptide-based ligands.

Integrin Receptor Studies: D-Cys Eptifibatide is widely utilized in research investigating the interactions between integrins and their ligands. Its cyclic structure and specific amino acid sequence enable it to mimic the binding motifs of natural ligands, making it an effective competitive inhibitor in integrin-binding assays. Researchers leverage its stability and affinity to dissect the molecular mechanisms governing cell adhesion, migration, and signal transduction. By employing this cyclic peptide in vitro, scientists can map binding sites, characterize receptor specificity, and elucidate the structural determinants underlying integrin-ligand recognition, thereby advancing the understanding of cell-extracellular matrix interactions.

Platelet Aggregation Analysis: In the context of hemostasis and thrombosis research, the cyclic nature of Eptifibatide analogs such as D-Cys Eptifibatide provides a robust tool for studying platelet aggregation processes. Its ability to interact with the glycoprotein IIb/IIIa complex on platelets enables detailed examination of aggregation pathways and the identification of key modulators involved in clot formation. By incorporating this compound into aggregation assays, investigators can assess the efficacy of new antiplatelet agents, investigate the dynamics of platelet activation, and explore the contribution of integrin-mediated signaling to thrombus development.

Peptide Engineering and Modification: The inclusion of a D-cysteine residue in D-Cys Eptifibatide offers unique opportunities for peptide engineering. This non-natural amino acid enhances proteolytic stability and provides a functional group for site-specific conjugation. Researchers exploit this feature to introduce fluorescent labels, affinity tags, or other chemical moieties, thereby creating customized probes for imaging, affinity purification, or biosensing applications. The versatility of this peptide scaffold supports the development of multifunctional biomolecules tailored for diverse experimental needs in chemical biology and bioanalytical research.

Molecular Probe Development: D-Cys Eptifibatide serves as a valuable starting point for the design of molecular probes targeting integrin receptors and related proteins. Its high binding affinity and resistance to enzymatic breakdown make it suitable for applications requiring prolonged stability, such as live-cell imaging or in situ receptor mapping. Scientists utilize derivatives of this compound to visualize receptor distribution, monitor ligand-receptor dynamics, and quantify target engagement in complex biological systems, thereby facilitating the discovery and validation of new therapeutic targets.

Drug Discovery and Structure-Activity Relationship (SAR) Studies: The structural features of D-Cys Eptifibatide make it an attractive candidate for SAR studies aimed at optimizing peptide-based ligands. By systematically modifying its amino acid composition or cyclic structure, researchers can evaluate the impact on binding affinity, selectivity, and biological activity. These investigations yield insights into the structural requirements for effective integrin antagonism and inform the rational design of next-generation peptides with improved pharmacological profiles. The adaptability of this compound in SAR workflows accelerates the identification of lead candidates for further preclinical evaluation.

Bioconjugation and Targeted Delivery: The D-cysteine moiety within D-Cys Eptifibatide provides a chemically reactive site for the attachment of diverse payloads, such as nanoparticles, imaging agents, or therapeutic molecules. Researchers exploit this property to create targeted delivery systems that harness the peptide's integrin-binding capability for selective localization to specific cell types or tissues. By integrating D-Cys Eptifibatide into bioconjugates, scientists can enhance the specificity and efficacy of drug delivery platforms, develop targeted imaging agents for diagnostic applications, and design multifunctional constructs for theranostic research. These innovative approaches underscore the compound's versatility and its expanding role in the development of precision tools for biomedical research.

1. Tachykinin-related peptides modulate immune-gene expression in the mealworm beetle Tenebrio molitor L

2. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

3. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation

4. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

5. TMEM16F and dynamins control expansive plasma membrane reservoirs